Running Head Epstein Barr-Virus identifying Sites Bound By Epstein-Barr Virus Nuclear Antigen 1 (Ebna1) In The Human Genome Defining A Position-Weighted Matrix To Predict Sites Bound By Ebna1 In Viral Genomes

Read Complete Research Material

RUNNING HEAD EPSTEIN BARR-VIRUS

Identifying Sites Bound by Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) in the Human Genome Defining a Position-Weighted Matrix To Predict Sites Bound by EBNA1 in Viral Genomes



Epstein Barr-Virus

Article Identifying Sites Bound by Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) in the Human Genome Defining a Position-Weighted Matrix To Predict Sites Bound by EBNA1 in Viral Genomes.

Scientific Background

Epstein-Barr nuclear antigen 1 (EBNA1) is a multifunctional, dimeric viral protein associated with Epstein-Barr virus. It is the only viral protein of Epstein-Barr that is found in all EBV-related malignancies. It is important in establishing and maintaining the altered state that cells take when infected with EBV. EBNA1 possesses a glycine-alanine repeat sequence that separates the protein into amino- and carboxy-terminal domains. This sequence also seems to stabilize the protein, preventing proteasomal breakdown, as well as impairingantigen processing and MHC class I-restricted antigen presentation. This thereby inhibits the CD8-restricted cytotoxic T cell response against virus-infected cells. The EBNA1 transcript area originates at the Qp promoter during latency phases I and II. It is the only viral protein expressed during the first latency phase.

EBNA1 is integral in many EBV functions including gene regulation, extrachromosomal replication, and maintenance of the EBV episomal genome through positive and negative regulation of viral promoters. Studies show that the phosphorylation of ten specific sites on EBNA1 regulates these functions. When phosphorylation does not occur, replication and transcription activities of the protein are significantly decreased. EBNA1 acts through sequence-specific binding to the plasmid origin of viral replication (oriP) within the viral episome. The oriP has four EBNA1 binding sites where replication is initiated as well as a 20-site repeat segment which also enhances the presence of the protein. EBNA1's specific binding ability, as well as its ability to tether EBV DNA to chromosomal DNA, allows EBNA1 to mediate replication and partitioning of the episome during division of the host cell. EBNA1 also interacts with some viral promoters via several mechanisms, further contributing to transcriptional regulation of EBNA1 itself as well as the other EBNAs (2 and 3) and of EBV latent membrane protein 1 (LMP1).

Though EBNA1 is a well-characterized protein, its role in oncogenesis is less well-defined. It is consistently expressed in EBV-associated tumors. EBNA1 is the only identified latent protein-encoding genes that it consistently expressed in Burkitt's lymphoma cells and is believed to contribute to EBV malignancies through B cell-directed expression. This expression has the ability to produce B-cell lymphomas in transgenic mice and contribute to the survival of Burkitt's lymphoma in vitro. EBNA1 may regulate cellular genes during EBV's latency phase and thus regulate EBV associated tumors. Some studies suggest that it is possible that EBNA1 may be involved in the maintenance function in tumors.Transgenic mice expressing EBNA1 in B cell lines showed a predisposition to B cell lymphoma, thus demonstrating that EBNA1 is a viral oncogene and that it likely plays a role in B cellneoplasia. Data also show that, though its role in extrachromosomal replication, EBNA1 also increases the growth of B cells, thus aiding in the formation of malignancies.

Epstein-Barr virus (EBV) has infected more than 90% of the humankind. This gammaherpesvirus infection has been associated with Burkitt`s lymphoma as well as nasopharyngeal carcinoma. Also, it is relevant to know that 40% Hodgkin`s lymphoma and 14% carcinomas from gastrointestinal ...